Ryan Savitz Sells 31,249 Shares of Dianthus Therapeutics (NASDAQ:DNTH) Stock

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) EVP Ryan Savitz sold 31,249 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Dianthus Therapeutics Price Performance

Shares of DNTH opened at $101.28 on Wednesday. The company has a 50-day simple moving average of $88.20 and a two-hundred day simple moving average of $72.75. The firm has a market capitalization of $5.54 billion, a PE ratio of -24.52 and a beta of 1.20. Dianthus Therapeutics, Inc. has a one year low of $18.08 and a one year high of $102.37.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Tuesday, May 5th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.40 million. Analysts expect that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on DNTH. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Monday, April 20th. Wells Fargo & Company started coverage on shares of Dianthus Therapeutics in a research report on Thursday, March 19th. They issued an “overweight” rating and a $135.00 target price on the stock. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wedbush increased their price target on shares of Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $117.82.

Institutional Trading of Dianthus Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Horizon Corp purchased a new position in Dianthus Therapeutics during the first quarter valued at $32,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Dianthus Therapeutics during the fourth quarter valued at $40,000. Raymond James Financial Inc. bought a new position in shares of Dianthus Therapeutics during the second quarter valued at $27,000. Russell Investments Group Ltd. purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter worth about $64,000. Finally, ABS Direct Equity Fund LLC purchased a new position in shares of Dianthus Therapeutics in the 1st quarter worth about $179,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.